Today, nonsurgical therapies are typically considered for men with early-phase disease (ie, <12 months’ duration) characterized by unstable or progressive deformity and painful erections, as well as those who are not psychologically ready for or interested in surgery.1
* Potaba is approved in Germany and England. None of the other interventions are approved in any European country for Peyronie’s Disease.
Surgery is an option for severe curvature abnormality and/or treatment resistant erectile dysfunction in the stable phase of disease. It is often reserved for the most severe cases due to the potential risk of complications, including penile shortening, glans numbness, neurovascular injury, infection and erectile dysfunction.4-6 Surgery aims to correct curvature and allow satisfactory intercourse. Reports vary however, in terms of:
– Reduction of curvature deformity3
– Side effects, such as penile shortening and erectile dysfunction3
- Ralph D et al. J Sex Med. 2010;7(7):2359-2374.
- Xiapex Summary of Product Characteristics.
- Hatzimouratidis K et al, European Urology 62 (2012) 543–552.
- Taylor FL and Levine LA. Urol Clin N Am 34 (2007) 517–534.
- Chung E et al. J Sex Med 2011;8:594–600.
- Benson J et al. Current Urology Reports 2009, 10:468–474.